InnovAge Holding (INNV) Faces A Valuation Test Following Its Shelf Registration
InnovAge Holding (INNV) has filed a shelf registration for up to US$1.31 billion of common stock, covering 112,988,070 shares. This filing gives the company scope to raise equity capital when conditions appear suitable.
See our latest analysis for InnovAge Holding.
The shelf registration arrives after a strong period for InnovAge Holding, with the share price up 36.54% over 90 days and a year to date share price return of 118.88%. The 1 year total shareholder return of 262.94% points to building momentum despite a recent pullback.
If you are weighing what else might be reshaping healthcare, it could be worth seeing which other companies are attracting attention through our screener of 41 healthcare AI stocks.
After InnovAge Holding’s sharp rebound and a shelf that could add a large pool of new shares, the real tension is simple: Does buying today make sense, or is it better to wait for a cleaner entry on valuation?
Most Popular Narrative: 62.3% Overvalued
Analysts see InnovAge Holding’s fair value at $7.00 per share, which sits well below the last close of $11.36 and sets up a clear valuation gap to unpack.
In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 7.1x on those 2029 earnings, up from -104.9x today. This future PE is lower than the current PE for the US Healthcare industry at 22.7x.
Want to understand why a relatively low future earnings multiple still supports that $7.00 figure? The narrative focuses on firm revenue gains, rising margins and a sharp swing into profitability, all evaluated using a discount rate that keeps every forecast on a tight leash.
Result: Fair Value of $7.00 (OVERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, InnovAge Holding still faces cost of care rising faster than revenue, as well as ongoing regulatory and compliance pressures that could quickly challenge the current overvaluation story.
Find out about the key risks to this InnovAge Holding narrative.
Another View on InnovAge Holding’s Valuation
The analyst fair value for InnovAge Holding is $7.00 per share, which presents the stock as overvalued relative to that target. Our DCF model points in a very different direction and suggests the future cash flow value is $29.57 per share. This implies a wide gap that investors will want to examine carefully.
Look into how the SWS DCF model arrives at its fair value.
Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out InnovAge Holding for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 55 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.
Next Steps
If the mixed tone on InnovAge Holding leaves you unsure, now is a good time to review the key data yourself and decide what feels reasonable. To see what is driving optimism in the story, take a closer look at the 2 key rewards.
Looking for more investment ideas beyond InnovAge Holding?
Do not stop with InnovAge Holding when there are other stocks that could fit your style. Use the Simply Wall St screener to line up fresh candidates fast.
- Target income first and see which companies qualify as 9 dividend fortresses for investors who want yields supported by solid fundamentals.
- Hunt for mispriced quality and review the 55 high quality undervalued stocks that combine strong balance sheets with appealing valuations.
- Prioritise capital protection and scan the 81 resilient stocks with low risk scores that aim to keep volatility and financial risk in check.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com